India’s pharmaceutical exports to the United States could face fresh challenges if Washington moves ahead with its proposed tariffs on generic medicines, according to the Global Trade Research Initiative (GTRI). The trade policy think tank has cautioned that such a move could significantly affect India’s drug manufacturers, which rely heavily on the US as their largest overseas market.
India is one of the world’s leading suppliers of affordable generic medicines and plays a crucial role in meeting US healthcare demand. A substantial share of India’s pharmaceutical exports is directed to the US, making the sector particularly vulnerable to changes in American trade policy.
According to GTRI, the proposed tariffs could increase the cost of Indian generic drugs in the US market, reducing their price competitiveness against domestic manufacturers and suppliers from other countries. The measure could also disrupt established supply chains and place additional financial pressure on Indian pharmaceutical exporters.
Industry experts believe any increase in tariffs may ultimately raise healthcare costs for American consumers, as Indian generic medicines are widely used to provide cost-effective treatment across a range of therapeutic categories. The move could also prompt companies to reassess pricing strategies and explore alternative export markets to reduce dependence on the US.
While the proposal is still under consideration, GTRI has urged policymakers and industry stakeholders to closely monitor developments and pursue diplomatic engagement to safeguard India’s pharmaceutical exports. The think tank noted that maintaining stable market access to the US remains critical for sustaining the growth of India’s pharmaceutical industry and preserving its position as a global leader in generic drug manufacturing.
